Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

28. August 2013 08:00 ET | Quelle: Galectin Therapeutics Inc.

Galectin Therapeutics Announces Update on Warrant Exercises

NORCROSS, Ga., Aug. 28, 2013 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today...
21. August 2013 08:00 ET | Quelle: Galectin Therapeutics Inc.

Galectin Therapeutics Announces $3 Million Private Placement of Restricted Stock

NORCROSS, Ga., Aug. 21, 2013 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today...
14. August 2013 16:00 ET | Quelle: Galectin Therapeutics Inc.

Galectin Therapeutics Reports Second Quarter 2013 Financial Results

NORCROSS, Ga., Aug. 14, 2013 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today...
12. August 2013 08:00 ET | Quelle: Galectin Therapeutics Inc.

Galectin Therapeutics Receives FDA Fast Track Designation for GR-MD-02 for Fatty Liver Disease With Advanced Fibrosis

NORCROSS, Ga., Aug. 12, 2013 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced...
05. August 2013 08:00 ET | Quelle: Galectin Therapeutics Inc.

Reduction in Lung Fibrosis With the Anti-Galectin Drug GR-MD-02 Revealed in Preclinical Data

NORCROSS, Ga., Aug. 5, 2013 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced...